Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 2;9(77):34520-34527.
doi: 10.18632/oncotarget.26145.

Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study

Takatsugu Ogata  1 , Hironaga Satake  2 , Misato Ogata  1 , Yukimasa Hatachi  1 , Kentaro Inoue  3 , Madoka Hamada  3 , Hisateru Yasui  1
Affiliations

Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study

Takatsugu Ogata et al. Oncotarget. .

Abstract

Introduction: The neutrophil-to-lymphocyte ratio (NLR) is effective as a predictive factor for lung cancer treated with nivolumab. The objective of this study was to determine the effectiveness of NLR for patients with advanced gastric cancer (AGC) treated with nivolumab.

Methods: This was a multicenter, retrospective study of patients with AGC treated with nivolumab from June 2017 to December 2017. The NLRs were calculated before the first cycle (NLRpre) and two weeks after the first administration (NLRpost).

Results: Twenty-six patients were enrolled (males 19, females 7) with a median age of 64 years. The overall response rate was 15%. The median PFS was 80 days (range, 11 - 265) and the median OS was 290 days (range, 21 - 332). Stratified with high NLR (≥5) and low NLR (<5), the median PFS was shorter in the high NLRpre arm (87 vs. 45 days; p=0.066) and significantly shorter in the high NLRpost arm (94 vs. 28 days; p=0.014). The median OS was significantly shorter in the high NLRpre arm (290 vs. 175 days; p=0.008) and in the high NLRpost arm (290 vs. 69 days; p<0.001).

Conclusion: NLR may be an effective prognostic factor in patients with AGC treated with nivolumab.

Keywords: advanced gastric cancer; neutrophil-to-lymphocyte ratio; nivolumab; predictive factors; prognostic factors.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST None.

Figures

Figure 1
Figure 1. Progression free survival of NLRpre and NLRpost
(A) Kaplan–Meier survival curve according to the NLRpre. (B) Kaplan–Meier survival curve according to the NLRpost.
Figure 2
Figure 2. Overall survival of NLRpre and NLRpost
(A) Kaplan–Meier survival curve according to the NLRpre. (B) Kaplan–Meier survival curve according to the NLRpost.
See this image and copyright information in PMC

References

    1. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71. doi: 10.1016/S0140-6736(17)31827-5. - DOI - PubMed
    1. Japanese Gastric Cancer Association (JGCA) Gastric Cancer Treatment Guidelines, 5th edition. Tokyo: Kanehara Inc; 2018.
    1. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88:218–30. doi: 10.1016/j.critrevonc.2013.03.010. - DOI - PubMed
    1. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124. doi: 10.1093/jnci/dju124. - DOI - PubMed
    1. Tanaka H, Muguruma K, Toyokawa T, Kubo N, Ohira M, Hirakawa K. Differential impact of the neutrophil-lymphocyte ratio on the survival of patients with stage IV gastric cancer. Dig Surg. 2014;31:327–33. doi: 10.1159/000369278. - DOI - PubMed

LinkOut - more resources